Literature DB >> 13763699

Vancomycin in severe staphylococcal infections.

D B LOURIA, T KAMINSKI, J BUCHMAN.   

Abstract

Entities:  

Keywords:  ANTIBIOTICS/therapy; STAPHYLOCOCCAL INFECTIONS/therapy

Mesh：

Substances：

Year:  1961        PMID： 13763699     DOI： 10.1001/archinte.1961.03620020075007

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN： 0003-9926


× No keyword cloud information.
  9 in total

1.  Acute staphylococcal endocarditis in a patient with ventricular septal defect.

Authors:  J M PEARCE
Journal:  Br Med J       Date:  1963-05-04

2.  Infectious disease emergencies. Part II: patients presenting with cardiac decompensation or circulatory insufficiency (shock).

Authors: 
Journal:  West J Med       Date:  1976-08

3.  Vancomycin Serum Concentration Monitoring : The Middle Ground is Best.

Authors:  F Marra; B Cairns; P Jewesson
Journal:  Clin Drug Investig       Date:  1996-08       Impact factor: 2.859

Review 4.  An updated comparison of drug dosing methods. Part IV: Vancomycin.

Authors:  R D Pryka; K A Rodvold; S M Erdman
Journal:  Clin Pharmacokinet       Date:  1991-06       Impact factor: 6.447

Review 5.  Pharmacokinetic optimisation of vancomycin therapy.

Authors:  W G Leader; M H Chandler; M Castiglia
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

6.  Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections.

Authors:  J K James; S M Palmer; D P Levine; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 7.  Vancomycin: pharmacokinetics and administration regimens in neonates.

Authors:  Matthijs de Hoog; Johan W Mouton; John N van den Anker
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 8.  The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents.

Authors:  J M Hyatt; P S McKinnon; G S Zimmer; J J Schentag
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

9.  In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  E Löwdin; I Odenholt; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.